A Phase II Trial of Stereotactic Ablative Body Radiotherapy for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life, and Disease Control Outcomes with 5-Year Minimum Follow-Up

Purpose/Objective(s): Herein, we report the results of an IRB-approved phase II trial of Varian Trilogy/TrueBeam-based stereotactic ablative body radiotherapy (SABR) monotherapy for low-risk prostate cancer using the Calypso(®) System to provide real-time electromagnetic tracking of the prostate’s p...

Descripción completa

Detalles Bibliográficos
Autor principal: Mantz, Constantine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231837/
https://www.ncbi.nlm.nih.gov/pubmed/25452933
http://dx.doi.org/10.3389/fonc.2014.00279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231837/
https://www.ncbi.nlm.nih.gov/pubmed/25452933
http://dx.doi.org/10.3389/fonc.2014.00279

Ejemplares similares